Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes

clinicaltrials.gov/study/NCT06390748

Is a

‌

Clinical study

Clinical Study attributes

NCT Number

NCT063907480

Health Conditions in Trial

Sepsis

‌

Cytokine storm

Trial Recruitment Size

1050

Trial Sponsor

‌

Lin Chen

Clinical Trial Start Date

January 1, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Clinical Trial Study Type

Interventional0

Interventional Trial Purpose

Treatment0

Intervention Type

Drug0

Interventional Trial Phase

Phase 20

Official Name

Investigating the Immunomodulatory Effects of Esmolol in Sepsis Management and Its Impact on Patient Outcomes0

Last Updated

April 30, 2024

Allocation Type

Randomized0

Intervention Model

Parallel Assignment0

Masking Type

Single0

Masked Party

Participant0

Other attributes

Intervention Treatment

esmolol0

Study summary

Evaluate the effectiveness of esmolol, a selective β1-adrenergic receptor blocker, in modulating immune responses and improving patient outcomes in sepsis.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes

Contents

Clinical Study attributes

Other attributes

Timeline

Further Resources

References

Find more entities like Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes